111 Capital Acadia Pharmaceuticals Inc Transaction History
111 Capital
- $518 Billion
- Q1 2025
A detailed history of 111 Capital transactions in Acadia Pharmaceuticals Inc stock. As of the latest transaction made, 111 Capital holds 10,767 shares of ACAD stock, worth $236,658. This represents 0.03% of its overall portfolio holdings.
Number of Shares
10,767Holding current value
$236,658% of portfolio
0.03%Shares
1 transactions
Others Institutions Holding ACAD
# of Institutions
351Shares Held
165MCall Options Held
1.77MPut Options Held
307K-
Baker Bros. Advisors LP New York, NY42.9MShares$942 Million8.49% of portfolio
-
Vanguard Group Inc Valley Forge, PA15.2MShares$334 Million0.0% of portfolio
-
Black Rock Inc. New York, NY12.1MShares$265 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY8.54MShares$188 Million2.32% of portfolio
-
State Street Corp Boston, MA6.99MShares$154 Million0.0% of portfolio
About ACADIA PHARMACEUTICALS INC
- Ticker ACAD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 161,843,008
- Market Cap $3.56B
- Description
- ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...